Underrated Dividend Stocks with Low Yields
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Microsoft Dividend Growth: Microsoft offers a 0.9% dividend yield, lower than the S&P 500's 1.1%, yet its dividend has surged by 153% over the past decade to $0.91 per share quarterly, indicating strong growth potential and room for future increases.
- Eli Lilly's Appeal: Eli Lilly's dividend yield stands at 0.6%, but its quarterly payout has more than doubled from $0.85 in 2021 to $1.73, reflecting a five-year growth trajectory, while its low payout ratio of 22% suggests sustainable future dividend increases.
- Mastercard's Solid Performance: Mastercard's dividend yield is 0.7%, but its quarterly dividend has risen from $0.19 a decade ago to $0.87, marking a 358% increase, showcasing robust business fundamentals and optimism for continued growth.
- Investment Value Analysis: Despite lower yields, Microsoft, Eli Lilly, and Mastercard's strong growth and low payout ratios position them as reliable long-term investments, providing investors with stable income streams.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1122.500
Low
950.00
Averages
1192
High
1500
Current: 1122.500
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Strong Growth Potential Amid GLP-1 Focus
- Market Performance Review: Eli Lilly's market cap has returned to $1 trillion, with a modest 5% stock increase this year, yet an impressive over 400% return over the past five years highlights its strong performance in the GLP-1 weight loss market and investor confidence.
- Profitability Enhancement: The company's net income for the past 12 months reached $25.3 billion, a significant increase from a couple of years ago, indicating sustained profitability that provides robust financial support for future investments.
- Strategic Acquisitions Expansion: Eli Lilly has recently acquired several healthcare companies, including Orna Therapeutics, aimed at expanding its RNA therapies and infectious disease portfolio, further solidifying its market position in the healthcare sector.
- Long-Term Investment Appeal: Despite a current P/E ratio of 40, Eli Lilly is still viewed as a strong long-term investment option, particularly given its management's commitment to operational diversification and future growth prospects.
See More
Novo Nordisk to Seek Approval for Weight-Loss Pill Soon
- Increased Market Competition: CEO Mike Doustdar announced that Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill “very soon,” aiming to catch up with rival Eli Lilly's leading position in the world's second-largest pharmaceutical market.
- Strategic Positioning: This move not only reflects Novo Nordisk's commitment to the Chinese market but also indicates its intention to meet the growing health demands through the launch of its weight-loss medication, thereby enhancing its market share in the rapidly evolving pharmaceutical industry.
- Industry Outlook: With rising concerns over obesity in China, the weight-loss medication market holds significant potential, and Novo Nordisk's application is expected to drive product line diversification and improve overall performance in the future.
- Regulatory Challenges: While Novo Nordisk is actively advancing the approval process, the complex drug regulatory environment in China means that successfully obtaining approval will be a critical factor for the company's success in this market.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Underrated Dividend Stocks with Low Yields
- Microsoft Dividend Growth: Microsoft offers a 0.9% dividend yield, lower than the S&P 500's 1.1%, yet its dividend has surged by 153% over the past decade to $0.91 per share quarterly, indicating strong growth potential and room for future increases.
- Eli Lilly's Appeal: Eli Lilly's dividend yield stands at 0.6%, but its quarterly payout has more than doubled from $0.85 in 2021 to $1.73, reflecting a five-year growth trajectory, while its low payout ratio of 22% suggests sustainable future dividend increases.
- Mastercard's Solid Performance: Mastercard's dividend yield is 0.7%, but its quarterly dividend has risen from $0.19 a decade ago to $0.87, marking a 358% increase, showcasing robust business fundamentals and optimism for continued growth.
- Investment Value Analysis: Despite lower yields, Microsoft, Eli Lilly, and Mastercard's strong growth and low payout ratios position them as reliable long-term investments, providing investors with stable income streams.
See More
Low Yield, High Growth Dividend Stocks
- Microsoft Dividend Growth: Microsoft's quarterly dividend has increased from $0.36 a decade ago to $0.91 today, a 153% rise with a compounded annual growth rate (CAGR) of nearly 10%, and despite its 0.9% yield being below the S&P 500's 1.1%, its low payout ratio of 21% indicates significant room for future growth.
- Eli Lilly's Appeal: Eli Lilly's quarterly dividend has more than doubled in five years from $0.85 in 2021 to $1.73, and while its current yield is only 0.6%, its payout ratio of 22% suggests the company can continue to increase dividends while providing exposure to the fast-growing GLP-1 market.
- Mastercard's Solid Performance: Mastercard's quarterly dividend has surged from $0.19 a decade ago to $0.87, representing a 358% increase and a CAGR of over 16%, and although its yield is 0.7%, its low payout ratio of 18% and 47% sales growth indicate a strong business foundation and future growth potential.
- Investor Considerations: While these companies currently offer low dividend yields, their strong growth prospects and low payout ratios make them reliable income investment choices, and investors should focus on their long-term dividend growth potential.
See More
Market Momentum Broadens Beyond AI
- Market Performance Surge: As of Tuesday, the equal-weighted S&P 500 has risen 10.4% this year, compared to a 9.7% increase in the market cap-weighted version, indicating that the equal-weight index is on track to outperform the traditional S&P 500 for the first time since 2022, reflecting broad market interest in emerging technologies.
- Geopolitical Influence: Citigroup strategist Scott Chronert pointed out that easing tensions between the U.S. and Iran are driving broader market gains, with market optimism significantly boosted by the positive sentiment surrounding current Iran negotiations.
- Healthcare Sector Opportunities: Despite the S&P 500 healthcare sector declining over 1% this year, UBS's Gerry Fowler believes the sector's appeal is increasing, particularly in the U.S., where themes reflecting accelerating growth are becoming as attractive as long-standing AI capex beneficiaries.
- Software Sector Recovery: Although the iShares Expanded Tech-Software Sector ETF is down 13% year-to-date, it has gained over 14% in the second quarter, indicating improved earnings revisions in the software sector that could provide additional growth momentum.
See More
Eli Lilly's Strong Growth Potential Amid GLP-1 Focus
- Market Performance Review: Eli Lilly's market cap has returned to $1 trillion, with a modest 5% stock increase this year, yet an impressive over 400% return over the past five years highlights its strong performance in the GLP-1 weight loss market and investor confidence.
- Profitability Enhancement: The company's net income for the past 12 months reached $25.3 billion, a significant increase from a couple of years ago, indicating sustained profitability that provides robust financial support for future investments.
- Strategic Acquisitions Expansion: Eli Lilly has recently acquired several healthcare companies, including Orna Therapeutics, aimed at expanding its RNA therapies and infectious disease portfolio, further solidifying its market position in the healthcare sector.
- Long-Term Investment Appeal: Despite a current P/E ratio of 40, Eli Lilly is still viewed as a strong long-term investment option, particularly given its management's commitment to operational diversification and future growth prospects.
See More
Novo Nordisk to Seek Approval for Weight-Loss Pill Soon
- Increased Market Competition: CEO Mike Doustdar announced that Novo Nordisk plans to seek Chinese regulatory approval for its weight-loss pill “very soon,” aiming to catch up with rival Eli Lilly's leading position in the world's second-largest pharmaceutical market.
- Strategic Positioning: This move not only reflects Novo Nordisk's commitment to the Chinese market but also indicates its intention to meet the growing health demands through the launch of its weight-loss medication, thereby enhancing its market share in the rapidly evolving pharmaceutical industry.
- Industry Outlook: With rising concerns over obesity in China, the weight-loss medication market holds significant potential, and Novo Nordisk's application is expected to drive product line diversification and improve overall performance in the future.
- Regulatory Challenges: While Novo Nordisk is actively advancing the approval process, the complex drug regulatory environment in China means that successfully obtaining approval will be a critical factor for the company's success in this market.
See More
Market Volatility and Portfolio Performance Overview
- Market Volatility Overview: The S&P 500 experienced significant volatility over the past three weeks, recording its worst session in eight months on June 5, just after reaching record highs, indicating shifts in market sentiment and investor uncertainty.
- Portfolio Performance: Among 34 stocks, 19 have risen since the May meeting, with Arm's stock soaring 38.2% driven by strong AI demand and the release of a new Nvidia chip, highlighting the potential for a rebound in tech stocks.
- Bank Stocks Recovery: Wells Fargo's shares increased by 13.9%, reflecting the financial sector's status as the best-performing group in the S&P 500, although it remains down nearly 7% year-to-date, suggesting a cautious recovery amid potential earnings volatility.
- Underperforming Stocks: Amazon's stock fell 10.8%, primarily due to concerns over AI investments, despite securing a $17.5 billion loan for AI development, raising questions about its future financial health and investor confidence.
See More
Underrated Dividend Stocks with Low Yields
- Microsoft Dividend Growth: Microsoft offers a 0.9% dividend yield, lower than the S&P 500's 1.1%, yet its dividend has surged by 153% over the past decade to $0.91 per share quarterly, indicating strong growth potential and room for future increases.
- Eli Lilly's Appeal: Eli Lilly's dividend yield stands at 0.6%, but its quarterly payout has more than doubled from $0.85 in 2021 to $1.73, reflecting a five-year growth trajectory, while its low payout ratio of 22% suggests sustainable future dividend increases.
- Mastercard's Solid Performance: Mastercard's dividend yield is 0.7%, but its quarterly dividend has risen from $0.19 a decade ago to $0.87, marking a 358% increase, showcasing robust business fundamentals and optimism for continued growth.
- Investment Value Analysis: Despite lower yields, Microsoft, Eli Lilly, and Mastercard's strong growth and low payout ratios position them as reliable long-term investments, providing investors with stable income streams.
See More
Low Yield, High Growth Dividend Stocks
- Microsoft Dividend Growth: Microsoft's quarterly dividend has increased from $0.36 a decade ago to $0.91 today, a 153% rise with a compounded annual growth rate (CAGR) of nearly 10%, and despite its 0.9% yield being below the S&P 500's 1.1%, its low payout ratio of 21% indicates significant room for future growth.
- Eli Lilly's Appeal: Eli Lilly's quarterly dividend has more than doubled in five years from $0.85 in 2021 to $1.73, and while its current yield is only 0.6%, its payout ratio of 22% suggests the company can continue to increase dividends while providing exposure to the fast-growing GLP-1 market.
- Mastercard's Solid Performance: Mastercard's quarterly dividend has surged from $0.19 a decade ago to $0.87, representing a 358% increase and a CAGR of over 16%, and although its yield is 0.7%, its low payout ratio of 18% and 47% sales growth indicate a strong business foundation and future growth potential.
- Investor Considerations: While these companies currently offer low dividend yields, their strong growth prospects and low payout ratios make them reliable income investment choices, and investors should focus on their long-term dividend growth potential.
See More
Market Momentum Broadens Beyond AI
- Market Performance Surge: As of Tuesday, the equal-weighted S&P 500 has risen 10.4% this year, compared to a 9.7% increase in the market cap-weighted version, indicating that the equal-weight index is on track to outperform the traditional S&P 500 for the first time since 2022, reflecting broad market interest in emerging technologies.
- Geopolitical Influence: Citigroup strategist Scott Chronert pointed out that easing tensions between the U.S. and Iran are driving broader market gains, with market optimism significantly boosted by the positive sentiment surrounding current Iran negotiations.
- Healthcare Sector Opportunities: Despite the S&P 500 healthcare sector declining over 1% this year, UBS's Gerry Fowler believes the sector's appeal is increasing, particularly in the U.S., where themes reflecting accelerating growth are becoming as attractive as long-standing AI capex beneficiaries.
- Software Sector Recovery: Although the iShares Expanded Tech-Software Sector ETF is down 13% year-to-date, it has gained over 14% in the second quarter, indicating improved earnings revisions in the software sector that could provide additional growth momentum.
See More
